Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoimmunotargeted Therapy in Metastatic, Persistent and Recurrent Cervical Cancer
NCT07472153Phase 3Recruiting
- Sponsor
- N.N. Alexandrov National Cancer Centre of Belarus
- Start
- Jul 2025
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 3, randomised trial in Cervical Cancer (CC) (3 arms), sponsored by N.N. Alexandrov National Cancer Centre of Belarus. Primary endpoint: Overall Survival at 36 months. Started Jul 2025; status: recruiting.
02
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07472153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472153.